|

Dabrafenib Clinical Trials

14 actively recruiting trials across 5 locations

Also known as: BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Open cohort +1 more

Pipeline

Phase 1: 3Phase 2: 8Phase 3: 1Phase 4: 1

Top Sponsors

  • Tianjin Medical University Second Hospital1
  • The Netherlands Cancer Institute1
  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University1
  • Se Jun Park1
  • Rina Plattner1

Indications

  • Cancer14
  • Solid Tumor3
  • Lung Cancer2
  • BRAF V600K Mutation Present1
  • BRAF NP_004324.2:p.V600E1

Other9 trials

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
Phase 2
Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
Phase 2
Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations
Phase 2
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
Melanoma Metastasized to the Brain and Steroids
Phase 2
Precision Cancer Therapy in Rare Cancers
Phase 2
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Phase 2

Scottsdale, Arizona1 trial

Dabrafenib and/or Trametinib Rollover Study

Honor Health Research Institute

Phase 4

Fort Smith, Arkansas1 trial

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Mercy Hospital Fort Smith

Phase 3

Duarte, California1 trial

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

City of Hope Medical Center

Phase 1

Iowa City, Iowa1 trial

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

University of Iowa

Phase 1

Boston, Massachusetts1 trial

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

Massachusetts General Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.